文献速递免疫规划卫生政策与健康促进

在波多黎各实施登革热疫苗「接种前筛查」策略的公共卫生影响与成本效果

Public health impact and cost-effectiveness of implementing a 'pre-vaccination screening' strategy with the dengue vaccine in Puerto Rico.
PubMed 文献 · Vaccine · 2022-11-05

本研究基于已发表的登革热传播模型,评估在波多黎各采用三种检测方法(IgG ELISA、快速诊断检测、两者序贯)实施登革热疫苗(CYD-TDV)接种前筛查策略的10年公共卫生影响与成本效果。结果显示三种策略均可减少病例和伤残调整生命年,支付方视角下具有成本效果,社会视角下均节省成本,支持WHO和CDC的接种前筛查指导。

要点

  • 基于ELISA、RDT及两者序贯的接种前筛查策略在波多黎各10年内均可减少登革热病例和DALY。
  • 三种策略从支付方视角均具成本效果,从社会视角均节省成本。
  • 研究结果支持WHO和CDC关于CYD-TDV接种前筛查的指导。

核心结论

  • 本研究支持WHO和CDC关于CYD-TDV实施的接种前筛查指导。
  • 在波多黎各,无论采用何种检测策略,即使检测率相对较低,从支付方视角均具成本效果,从社会视角均节省成本。

研究设计与样本

  • 本研究基于先前发表的用于评估登革热疫苗接种获益/风险的传播模型开展分析。
  • 评估了三种接种前筛查检测方法:IgG酶联免疫吸附试验(ELISA)登革热血清检测、快速诊断检测(RDT)登革热血清检测、以及两者序贯使用(波多黎各推荐的方式)。
  • 考虑的时间跨度为10年。

主要发现

  • 在波多黎各,基于ELISA的方案、基于RDT的方案和两者序贯方案分别可避免中位1,192(95%CI:716-2,232)、2,812(95%CI:1,579-5,019)和1,017(95%CI:561-1,738)个伤残调整生命年(DALY)。
  • 上述获益来自病例减少:分别减少中位24,961(95%CI:17,480-36,782)、58,273(95%CI:40,729-84,796)和20,775(95%CI:14,637-30,374)例病例。
  • 从支付方视角,每避免一个DALY的成本分别为12,518美元(95%CI:4,749-26,922美元)、10,047美元(95%CI:3,350-23,852美元)和12,334美元(95%CI:4,965-26,444美元)。
  • 所有三种策略从社会视角均节省成本。

临床怎么用

  • WHO推荐将「接种前筛查」作为使用已获批登革热疫苗(CYD-TDV;Dengvaxia,赛诺菲)时的首选实施策略,即仅对既往登革热感染者接种。
  • 美国CDC推荐在登革热流行地区使用CYD-TDV预防有既往实验室确诊登革热感染的儿童发生登革热。
  • 作者结论支持WHO和CDC关于CYD-TDV接种前筛查的指导。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The World Health Organization (WHO) recommended 'pre-vaccination screening' as its preferred implementation strategy when using the licensed dengue vaccine (CYD-TDV; Dengvaxia, Sanofi), so that only individuals with previous dengue infection are vaccinated. The US Centers for Disease Control and Prevention (CDC) recommended use of CYD-TDV to prevent dengue in children with previous laboratory-confirmed dengue infection in regions where dengue is endemic. Here, we evaluate the public health impact and cost-effectiveness of a 'pre-vaccination screening' strategy in Puerto Rico. METHODS: The current analysis builds upon a previously published transmission model used to assess the benefits/risks associated with dengue vaccination. For 'pre-vaccination screening', three alternative testing methods were assessed: one using an immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) dengue serotest, another with dengue serotesting using a rapid diagnostic test (RDT), and one using both sequentially (as recommended in Puerto Rico). The time horizon considered was 10 years. RESULTS: In Puerto Rico, the disability-adjusted life years (DALYs) averted for 'pre-vaccination screening' with an ELISA-based program, RDT-based program, and both sequentially would be a median 1,192 (95% CI: 716-2,232), 2,812 (95% CI: 1,579-5,019), and 1,017 (95% CI: 561-1,738), respectively. These benefits would arise from the reduction in cases: median 24,961 (95% CI: 17,480-36,782), 58,273 (95% CI: 40,729-84,796), 20,775 (95% CI: 14,637-30,374) fewer cases, respectively. The cost per DALY averted from a payer perspective would be US$12,518 (95 %CI: US$4,749-26,922), US$10,047 (95% CI: US$3,350-23,852), and US$12,334 (95% CI: US$4,965-26,444), respectively. All three strategies would be cost saving from a societal perspective. CONCLUSIONS: Our study supports the WHO and CDC 'pre-vaccination screening' guidance for CYD-TDV implementation. In Puerto Rico, regardless of the testing strategy and even with a relatively low rate of testing, it would be cost-effective from a payer perspective and cost saving from a societal perspective.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Thommes E, Coudeville L, Muhammad R, et al. Public health impact and cost-effectiveness of implementing a 'pre-vaccination screening' strategy with the dengue vaccine in Puerto Rico. Vaccine. 2022. PMID: 36347720. doi:10.1016/j.vaccine.2022.10.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。